PreludeDx and Quanterix announce breast cancer test validation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
April 17, 2026 8:33 AM EDTNovel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)-- PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on... More
